Michael W Traeger1,2, Sophia E Schroeder1,3, Edwina J Wright1,4,5,6, Margaret E Hellard1,4,5, Vincent J Cornelisse5,7,8, Joseph S Doyle1,5, Mark A Stoové1,4. 1. Disease Elimination Program, Public Health Discipline, Burnet Institute. 2. School of Population and Global Health, The University of Melbourne, Victoria, Australia. 3. Department of Clinical Sciences, Lund University, Malmö, Sweden. 4. School of Public Health and Preventive Medicine, Monash University. 5. Department of Infectious Diseases, The Alfred and Monash University. 6. Peter Doherty Institute of Infection and Immunity, University of Melbourne. 7. Central Clinical School, Monash University, Melbourne. 8. Melbourne Sexual Health Centre, Carlton, Victoria, Australia.
Abstract
Background: Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) is effective in reducing HIV risk in men who have sex with men (MSM). However, concerns remain that risk compensation in PrEP users may lead to decreased condom use and increased incidence of sexually transmitted infections (STIs). We assessed the impact of PrEP on sexual risk outcomes in MSM. Methods: We conducted a systematic review of open-label studies published to August 2017 that reported sexual risk outcomes in the context of daily oral PrEP use in HIV-negative MSM and transgender women. Pooled effect estimates were calculated using random-effects meta-analysis, and a qualitative review and risk of bias assessment were performed. Results: Sixteen observational studies and 1 open-label trial met selection criteria. Eight studies with a total of 4388 participants reported STI prevalence, and 13 studies with a total of 5008 participants reported change in condom use. Pre-exposure prophylaxis use was associated with a significant increase in rectal chlamydia (odds ratio [OR], 1.59; 95% confidence interval [CI], 1.19-2.13) and an increase in any STI diagnosis (OR, 1.24; 95% CI, .99-1.54). The association of PrEP use with STI diagnoses was stronger in later studies. Most studies showed evidence of an increase in condomless sex among PrEP users. Conclusion: Findings highlight the importance of efforts to minimize STIs among PrEP users and their sexual partners. Monitoring of risk compensation among MSM in the context of PrEP scale-up is needed to assess the impact of PrEP on the sexual health of MSM and to inform preventive strategies.
Background: Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) is effective in reducing HIV risk in men who have sex with men (MSM). However, concerns remain that risk compensation in PrEP users may lead to decreased condom use and increased incidence of sexually transmitted infections (STIs). We assessed the impact of PrEP on sexual risk outcomes in MSM. Methods: We conducted a systematic review of open-label studies published to August 2017 that reported sexual risk outcomes in the context of daily oral PrEP use in HIV-negative MSM and transgender women. Pooled effect estimates were calculated using random-effects meta-analysis, and a qualitative review and risk of bias assessment were performed. Results: Sixteen observational studies and 1 open-label trial met selection criteria. Eight studies with a total of 4388 participants reported STI prevalence, and 13 studies with a total of 5008 participants reported change in condom use. Pre-exposure prophylaxis use was associated with a significant increase in rectal chlamydia (odds ratio [OR], 1.59; 95% confidence interval [CI], 1.19-2.13) and an increase in any STI diagnosis (OR, 1.24; 95% CI, .99-1.54). The association of PrEP use with STI diagnoses was stronger in later studies. Most studies showed evidence of an increase in condomless sex among PrEP users. Conclusion: Findings highlight the importance of efforts to minimize STIs among PrEP users and their sexual partners. Monitoring of risk compensation among MSM in the context of PrEP scale-up is needed to assess the impact of PrEP on the sexual health of MSM and to inform preventive strategies.
Authors: Michael Silverberg; Derek D Satre; J Carlo Hojilla; Julia Marcus; Jonathan E Volk; Wendy Leyden; C Bradley Hare; Rulin C Hechter; E Jennifer Edelman Journal: Sex Transm Infect Date: 2019-08-23 Impact factor: 3.519
Authors: Olga Tymejczyk; Kelly Jamison; Preeti Pathela; Sarah Braunstein; Julia A Schillinger; Denis Nash Journal: AIDS Patient Care STDS Date: 2018-10 Impact factor: 5.078
Authors: Hanne M L Zimmermann; Lisa R Postma; Roel C A Achterbergh; Thijs Reyniers; Maarten F Schim van der Loeff; Maria Prins; Henry J C de Vries; Elske Hoornenborg; Udi Davidovich Journal: Arch Sex Behav Date: 2021-02-22